Team

Dr. Dong Wei is a Co-founder of Codone Biotech, and a seasoned biotech executive with over 20 years of global research & development and management experiences in the industry. Most recently, Dr. Wei was CEO of EdiGene, where in four and half years he transformed the company into a clinical-stage biotech with multiple therapeutic gene-editing platforms, obtaining the 1st IND approval and executing the 1st Phase I clinical trial of a gene-editing therapy in China. Before that, he was Chief Operating Officer at Treos Bio, Global Development Leader of late-stage development programs at Shire (now part of Takeda), Senior Director of Business Operation and Program Management at Johnson & Johnson Innovation Center at California, and held various R&D and business positions with increasing responsibilities at global biopharmaceutical companies including BioMarin, Elan, and Janssen, leading a number of clinical-stage programs across therapeutic areas including oncology, immunology, neurodegenerative diseases, and orphan genetic diseases. Prior to that, he was Senior Consultant and Manager at Deloitte Consulting, advising global life science and healthcare clients in Strategy & Operation areas, and worked on oncology drug discovery at Chiron as well as genomic technologies at Applied Biosystems. He has an MBA from the Wharton School of University of Pennsylvania, a Ph.D. in Microbiology from Michigan State University and a B.S. in Genetics from Peking University.

Dr. Ling-Jie Kong is a Co-founder of Codone Biotech, and a seasoned biotech executive with over 20 years of innovative drug discovery experiences in oncology, hematology, metabolic diseases and rare genetic disorders. Most recently, Dr. Kong was CTO/CSO of Porton Advanced Solutions, a gene and cell therapy CDMO company, where he led the gene and cell therapy，rare genetic diseases research and cGMP manufacturing efforts, playing an important role in shaping and implementing the overall strategy and execution of all the programs. Prior to that, he was an associate principal scientist at Merck and then vice president at ASC Therapeutics, leading numerus drug discovery programs including two clinical stage programs in gene and cell therapy with over 20 patents in gene therapy related areas. From 2017~2022, he served on the Gene Editing Committee of American Society of Gene and Cell Therapy (ASGCT). Dr. Kong has a BS degree from Shandong University, China, an MS degree from Institute of Genetics, Chinese Academy of Sciences, PhD in Biochemistry from North Carolina State University, and postdoc training at Dr. Joseph Nevins Lab at HHMI, Duke University.